ELISA/assay

Mouse alpha Synuclein oligomer ELISA Kit

MBS724099

48-Strip-Wells

440 USD

ELISA Kit

Mouse alpha Synuclein oligomer ELISA Kit

[alpha Synuclein oligomer]

[Mouse a Synuclein oligomer ELISA Kit]

[Alpha-synuclein; Alpha-synuclein; alpha-synuclein; synuclein alpha-140; non A-beta component of AD amyloid; synuclein, alpha (non A4 component of amyloid precursor); Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP]

[alpha-SYNo]

[a-SYNo]

[SNCA; SNCA; PD1; NACP; PARK1; PARK4; NACP; PARK1; NACP]

SYUA_HUMAN

Mouse

This assay has high sensitivity and excellent specificity for detection of SNCOalpha. No significant cross-reactivity or interference between SNCOalpha and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between SNCOalpha and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Typical Testing Data/Standard Curve (for reference only)

Samples: Serum, Plasma, Cell Culture Supernatants, Body Fluid And Tissue Homogenate. Assay Type: Quantitative Competitive. Sensitivity: 1.0 pg/mL.

Neurobiology

Intended Uses: This SNCOalpha ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Monkey SNCOalpha. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay: SNCOalpha ELISA kit applies the competitive enzyme immunoassay technique utilizing a polyclonal anti-SNCOalpha antibody and an SNCOalpha-HRP conjugate. The assay sample and buffer are incubated together with SNCOalpha-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the SNCOalpha concentration since SNCOalpha from samples and SNCOalpha-HRP conjugate compete for the anti-SNCOalpha antibody binding site. Since the number of sites is limited, as more sites are occupied by SNCOalpha from the sample, fewer sites are left to bind SNCOalpha-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The SNCOalpha concentration in each sample is interpolated from this standard curve.

586067

P37840.1

13,109 Da

Alpha-synuclein Signaling Pathway (137913); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloids Pathway (366238); Disease Pathway (530764); EGFR1 Signaling Pathway (198782); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson s disease. A major component of amyloid plaques in the brains of patients with Alzheimer s disease. Two alternatively spliced isoforms transcripts have been identified. Protein type: Adaptor/scaffold. Chromosomal Location of Human Ortholog: 4q21. Cellular Component: Golgi apparatus; nuclear outer membrane; rough endoplasmic reticulum; mitochondrion; lysosome; fibril; extracellular region; terminal button; cell cortex; inclusion body; cytosol; mitochondrial respiratory chain complex I; actin cytoskeleton; synaptic vesicle; platelet alpha granule membrane; growth cone; axon; perinuclear region of cytoplasm; cytoplasm; plasma membrane; ribosome; cell junction; nucleus. Molecular Function: identical protein binding; protein domain specific binding; zinc ion binding; histone binding; kinesin binding; microtubule binding; ferrous iron binding; caspase inhibitor activity; magnesium ion binding; beta-tubulin binding; phosphoprotein binding; protein N-terminus binding; Hsp70 protein binding; oxidoreductase activity; calcium ion binding; dynein binding; protein binding; copper ion binding; phospholipase binding; phospholipid binding; fatty acid binding; tau protein binding; alpha-tubulin binding. Biological Process: regulation of acyl-CoA biosynthetic process; adult locomotory behavior; positive regulation of apoptosis; response to lipopolysaccharide; positive regulation of endocytosis; dopamine biosynthetic process; positive regulation of neurotransmitter secretion; calcium ion homeostasis; response to magnesium ion; synapse organization and biogenesis; fibril organization and biogenesis; dopamine uptake; negative regulation of neuron apoptosis; response to drug; negative regulation of dopamine metabolic process; synaptic vesicle endocytosis; negative regulation of transporter activity; negative regulation of apoptosis; regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; negative regulation of norepinephrine uptake; mitochondrial membrane organization and biogenesis; microglial cell activation; negative regulation of transcription from RNA polymerase II promoter; negative regulation of caspase activity; negative regulation of monooxygenase activity; fatty acid metabolic process; regulation of dopamine secretion; negative regulation of dopamine uptake; negative regulation of histone acetylation; negative regulation of exocytosis; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; phospholipid metabolic process; receptor internalization; response to iron(II) ion; positive regulation of receptor recycling; aging; caspase activation; neutral lipid metabolic process; protein destabilization; negative regulation of microtubule polymerization; regulation of glutamate secretion; regulation of macrophage activation; positive regulation of peptidyl-serine phosphorylation; organelle ATP synthesis coupled electron transport; regulation of locomotion; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential. Disease: Parkinson Disease 4, Autosomal Dominant; Parkinson Disease 1, Autosomal Dominant; Dementia, Lewy Body

48-Strip-Wells

440 USD

96-Strip-Wells

640

5x96-Strip-Wells

2895

10x96-Strip-Wells

5415